HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Stewart R. Craig Evan W.J. Cameron William S. Walker Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Craig, S. R. Articles by Walker, W. S. Search for Related Content PubMed PubMed Citation Articles by Craig, S. R. Articles by Walker, W. S.

Ann Thorac Surg 1998;66:356-361
© 1998 The Society of Thoracic Surgeons

---

Original articles: general thoracic

Effect of blood transfusion on survival after esophagogastrectomy for carcinoma¹

^a Thoracic Surgical Unit, City Hospital, Edinburgh, United Kingdom

Accepted for publication March 9, 1998.

Address reprint requests to Mr Craig, Department of Cardiothoracic Surgery, Royal Infirmary of Edinburgh, Lauriston Place, Edinburgh EH3 9YW, UK

Background. There is growing evidence that blood transfusion is associated with clinical factors that can lead to transfusion-induced immunosuppression. This effect can be beneficial or deleterious.

Methods. The effect of perioperative allogeneic blood transfusion on survival was studied retrospectively in 524 patients who were discharged from the hospital after esophagogastrectomy for carcinoma performed in a single unit over a 10-year period.

Results. The median operative blood loss for the series was 500 mL (range, 50 to 3,750 mL). Three hundred thirty-five patients (64%) received a perioperative allogeneic blood transfusion related to esophagogastrectomy, and 189 (36%) did not. The median perioperative blood transfusion administered was 900 mL (range, 300 to 12,950 mL). Perioperative allogeneic blood transfusion was associated with reduced survival for patients in stage III (p < 0.05) at 1 year, but no significant difference was found in this stage at 3 or 5 years after resection. Stage III disease accounted for 250 (48%) of the 524 patients discharged.

Conclusions. Although perioperative allogeneic blood transfusion does not affect long-term survival after esophagogastrectomy for carcinoma, it does have a significant association with short-term survival in a group whose overall survival is often limited after resection. Attention should be directed toward minimizing operative blood loss and transfusing only for factors known to be clinically important, such as oxygen delivery and hemodynamics, not arbitrary hemoglobin levels.

This article has been cited by other articles:

				A. Eroglu, A. Turkyilmaz, Y. Aydin, A. F. Erdem, M. Tokur, and N. Karaoglanoglu The Use of the LigaSure Vessel Sealing System in Esophageal Cancer Surgery Ann. Thorac. Surg., December 1, 2007; 84(6): 2076 - 2079. [Abstract] [Full Text] [PDF]

				V. Voelter, C. Schuhmacher, R. Busch, C. Peschel, J. R. Siewert, and F. Lordick Incidence of anemia in patients receiving neoadjuvant chemotherapy for locally advanced esophagogastric cancer Ann. Thorac. Surg., September 1, 2004; 78(3): 1037 - 1041. [Abstract] [Full Text] [PDF]

				S. M. Langley, C. Alexiou, D. H. Bailey, and D. F. Weeden The influence of perioperative blood transfusion on survival after esophageal resection for carcinoma Ann. Thorac. Surg., June 1, 2002; 73(6): 1704 - 1709. [Abstract] [Full Text] [PDF]